Jim Cramer looks ahead to next week's market game plan

Key Concepts:

• Tariffs and their impact on the market
• Individual investor resilience
• Upcoming earnings season and key companies to watch (Financials, Blackrock, Goldman Sachs, Morgan Stanley, ASML, Bank of America, Johnson & Johnson, Abbott Labs, PepsiCo, Netflix, American Express, GM, Charles Schwab)
• Consumer Price Index (CPI) and Federal Reserve policy
• Retail sales slowdown
• Meme stocks (Palantir, Robinhood)
• Pharmaceutical stocks (Pfizer, Eli Lilly, Abbott Labs)
• GE turnaround
• Boeing's potential
• Capital One and Discover potential upside
• Kontoor Brands (Wrangler, Helly Hansen) as a buy

1. Market Overview and Tariff Impact:

• The market is currently overbought but showing resilience despite new tariff announcements.
• The Dow slipped 279 points, the S&P declined 0.33%, and the Nasdaq dipped 0.22%.
• Individual investors are undeterred by tariff concerns, driving demand for stocks.
• The White House is expected to announce draconian measures regarding Russia, likely affecting the oil market (Cramer believes oil is going lower).

2. Earnings Season Preview (Week Ahead):

• Monday: New tariffs to be studied; potential draconian announcements about Russia.
• Tuesday: Earnings season kicks off with financials. Key companies: JP Morgan (CEO Jamie Dimon), Wells Fargo (CEO Charlie Scharf), Citigroup (CEO Jane Fraser), Blackrock (CEO Larry Fink).
  • Focus on loan losses and spending slowdown in financials.
  • Blackrock is highlighted as a potentially exciting story due to its infrastructure component.
  • Consumer Price Index (CPI) report released; potential impact on Federal Reserve's interest rate policy.
• Wednesday: Goldman Sachs and Morgan Stanley earnings.
  • Expectations of terrific numbers and strong M&A and IPO market performance.
  • ASML (Dutch semiconductor capital equipment company) earnings; potential catalyst for another round of semi buying.
  • Johnson & Johnson earnings; talc lawsuits continue to be a concern.
• Thursday: Retail sales data released; concerns about a slowdown due to uncertainty in Washington.
  • Abbott Labs earnings; often misinterpreted negatively during earnings season, presenting a potential buying opportunity.
  • PepsiCo earnings; challenges from GLP-1 drugs, RFK Junior's stance on junk food, and health trends.
  • Netflix earnings (after the close); focus on ad tier performance, Squid Game impact, and NFL Christmas streaming advertising. High expectations, potential downside if numbers disappoint.
• Friday: American Express earnings; historically sells off after reporting, regardless of results.
  • GM earnings; expectations of a significant beat.
  • Charles Schwab earnings; potential for short sellers to target the stock at the opening.

3. Key Company Analysis and Recommendations:

• Blackrock: Largest asset repository in the world with a new infrastructure component. CEO Larry Fink is expected to deliver a positive story.
• Goldman Sachs and Morgan Stanley: Expected to benefit from a booming M&A and IPO market.
• ASML: Dutch semiconductor capital equipment company with an effective monopoly.
• Bank of America: Stock is considered cheap due to relentless selling from Berkshire Hathaway. Brian Moynihan is doing a great job. Cramer advises not to wait for Berkshire to finish selling.
• Johnson & Johnson: Talc lawsuits continue to weigh on the stock despite consistent performance.
• Abbott Labs: Often misinterpreted negatively during earnings season, presenting a potential buying opportunity.
• PepsiCo: Trades at a low multiple due to challenges from GLP-1 drugs and health trends.
• Netflix: High expectations for earnings; focus on ad tier, Squid Game, and NFL streaming.
• American Express: Stock tends to sell off after earnings, regardless of results. CEO Steve Squeri is highlighted as a great leader.
• GM: Beginning to resemble its old self, with expectations of a significant beat. CEO Bill Brown is crushing it.
• Charles Schwab: Championed by Cramer; potential for short sellers to target the stock at the opening.

4. Specific Stock Questions and Answers:

• Palantir (PLTR): Considered a meme stock with continued momentum. Cramer believes it's not too late to buy.
• Pfizer (PFE): Inexpensive but lacks a catalyst. Dividend yield is attractive, but stock may remain stagnant without new cancer formulations. Cramer prefers Eli Lilly and Abbott Labs in the pharma and med equipment sectors.
• General Electric (GE): Fabulous stock with a giant move. Larry Culp is expected to tell a great story. Trimming a little is acceptable, but Cramer is generally positive.
• Boeing (BA): Seems like a solid buy.

5. Investing Club Annual Meeting Teaser:

• The segment will feature answers to questions from Investing Club members.

6. Other Stocks Mentioned:

• Capital One and Discover (potential upside)
• Kontoor Brands (Wrangler, Helly Hansen) - Cramer family favorite, considered a buy.

7. Conclusion:

The market is showing resilience despite tariff concerns, with individual investors driving demand. Earnings season is crucial, with key companies in financials, tech, and consumer sectors reporting. Specific stocks like Blackrock, Goldman Sachs, ASML, Bank of America, Abbott Labs, and American Express are highlighted for potential opportunities or challenges. Be aware of potential post-earnings sell-offs in Abbott Labs, American Express, and Charles Schwab, regardless of their results.